AstraZeneca sells rights to (rosuvastatin) to Grünenthal

AstraZeneca (AZ) announced that it will sell the rights to rosuvastatin to Grünenthal in over 30 European countries. AZ will continue to manufacture and supply the drug to Grünenthal throughout the transition period.

Source:

PharmaTimes